Phase 4 Study of Dolutegravir (DTG) in Russian Federation
NCT03314064
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
43
Enrollment
INDUSTRY
Sponsor class
Conditions
Infection, Human Immunodeficiency Virus
HIV Infections
Interventions
DRUG:
Dolutegravir 50 mg
Sponsor
ViiV Healthcare